MDS/AML is further subclassified into cases with mutated TP53, cases with myelodysplasia-related gene mutations, myelodysplasia-related cytogenetic abnormalities and MDS/AML-NOS. This evidence concerns the gene TP53 and acute myeloid leukemia.